The significance of two different free light chain immunoassays for monitoring of disease activity in multiple myeloma patients
| Authors | |
|---|---|
| Year of publication | 2010 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | For most patients with a monoclonal immunoglobulin, measuring FLC is unlikely to have additional benefit for monitoring of disease activity with the notable exception of those with nonsecretory/oligosecretory myeloma. FLCs monitoring could identify patients with resistance to current therapy regimens more quickly than M-Ig determination. Conversely the most rapidly responding patients may have a worse outcome. FLCs measurement can help us also in patients with early relapse still on chemotherapy or in case of free light chains escape phenomenon. Because of the kappa/lambda FLC ratio calculation is strongly influenced by measurement errors, therefore we recommend the preferential use of relevant FLC concentration values. |
| Related projects: |